Bicara: Stock Decline On FICERA Abstract Release Creates Buying Opportunity

Group 1 - Bicara Therapeutics Inc. (NASDAQ: BCAX) released updated interim data from its phase 1/1b study using its bifunctional EGFR/TGF-beta in combination with KEYTRUDA (pembrolizumab) for the treatment of patients with 1st-line recurrent/metastatic head and neck squamous cell carcinoma [2] - The Biotech Analysis Central service offers a deep-dive analysis of many pharmaceutical companies, including a library of over 600 biotech investing articles and a model portfolio of 10+ small and mid-cap stocks [2] - The service is available for $49 per month, with a yearly plan offering a 33.50$399 per year [1]